title: [A search for the risk factors for hiccups and evaluation of antiemetic therapy in CDDP-based chemotherapy, using cluster analysis].
abstract: Hiccups are often observed in patients treated with cisplatin(CDDP)-based chemotherapy. It has been reported that gender and specific dosages of CDDP and antiemetic drugs(e.g., dexamethasone and 5-HT3 receptor antagonist)using standard therapy are major risk factors in the onset of hiccups. Recently, aprepitant has been added to the antiemetic therapy in CDDP-based chemotherapy. However, it is not known how the onset of hiccups takes place in antiemetic therapy including aprepitant according to the guideline. In this study, we used cluster analysis to classify 229 patients treated with CDDP-based chemotherapy, to investigate the effect of antiemetic therapy on the onset of hiccups and chemotherapy-induced nausea and vomiting(CINV). Our analysis indicated that aprepitant was not a major risk factor for the onset of hiccups in the high CDDP dose group(≥70 mg/m(2)). However, an effect of antiemesis was confirmed in the standard therapy with aprepitant. In conclusion, we suggest that aprepitant is effective for CINV, without causing the onset of hiccups in patients treated with high-dose CDDP-based chemotherapy.
authors.affiliation: Dept. of Pharmacy, Kinki University Hospital, Faculty of Medicine.
authors.forename: Hajime
authors.initials: H
authors.lastname: Asano
authors.forename: Mizuki
authors.initials: M
authors.lastname: Watanabe
authors.forename: Akinori
authors.initials: A
authors.lastname: Kawaguchi
authors.forename: Masashi
authors.initials: M
authors.lastname: Yanae
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Funakami
authors.forename: Tetsuyuki
authors.initials: T
authors.lastname: Wada
authors.forename: Sumio
authors.initials: S
authors.lastname: Matzno
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Yamazoe
authors.forename: Shozo
authors.initials: S
authors.lastname: Nishida
authors.forename: Seiji
authors.initials: S
authors.lastname: Ichida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D016000:Cluster Analysis; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D006606:Hiccup / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D044406:Receptors, Serotonin, 5-HT3 / Q000378:metabolism; D012307:Risk Factors; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000627:therapeutic use*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D044406:Receptors, Serotonin, 5-HT3; D058831:Serotonin 5-HT3 Receptor Antagonists; D003907:Dexamethasone; D002945:Cisplatin